AAAAAA
Results:
1-23
|
Results: 23
Authors:
POPE B
BROWN RD
GIBSON J
PETERSEN A
WILEY J
JOSHUA DE
Citation: B. Pope et al., THE FUNCTIONAL PHENOTYPE OF THE PRIMITIVE PLASMA-CELL IN PATIENTS WITH MULTIPLE-MYELOMA CORRELATES WITH THE CLINICAL STATE, Leukemia & lymphoma, 27(1-2), 1997, pp. 83-91
Authors:
LOSCO P
KONDA MT
COAD C
RICKARD KA
JOSHUA DE
Citation: P. Losco et al., EVALUATION OF 2 NEAR PATIENT TESTING INSTRUMENTS AT THE RPAH ANTICOAGULANT CLINIC, Thrombosis and haemostasis, 1997, pp. 2851-2851
Authors:
SHARLAND A
SNOWDON L
JOSHUA DE
GIBSON J
TILLER DJ
Citation: A. Sharland et al., HEMODIALYSIS - AN APPROPRIATE THERAPY IN MYELOMA-INDUCED RENAL-FAILURE, American journal of kidney diseases, 30(6), 1997, pp. 786-792
Authors:
JOSHUA DE
MACCALLUM S
GIBSON J
Citation: De. Joshua et al., ROLE OF ALPHA-INTERFERON IN MULTIPLE-MYELOMA, Blood reviews, 11(4), 1997, pp. 191-200
Authors:
JOSHUA DE
PENNY R
MATTHEWS JP
LAIDLAW CR
GIBSON J
BRADSTOCK K
WOLF M
GOLDSTEIN D
Citation: De. Joshua et al., AUSTRALIAN-LEUKEMIA-STUDY-GROUP-MYELOMA-II - A RANDOMIZED TRIAL OF INTENSIVE COMBINATION CHEMOTHERAPY WITH OR WITHOUT INTERFERON IN PATIENTS WITH MYELOMA, British Journal of Haematology, 97(1), 1997, pp. 38-45
Authors:
PETERSEN AJ
BROWN RD
GIBSON J
POPE B
LUO XF
SCHUTZ L
WILEY JS
JOSHUA DE
Citation: Aj. Petersen et al., NUCLEOSIDE TRANSPORTERS, BCL-2 AND APOPTOSIS IN CLL CELLS EXPOSED TO NUCLEOSIDE ANALOGS IN-VITRO, European journal of haematology, 56(4), 1996, pp. 213-220
Authors:
SHARLAND AF
SNOWDON L
JOSHUA DE
GIBSON J
TILLER DJ
Citation: Af. Sharland et al., MYELOMA AND RENAL-FAILURE, Kidney international, 50(4), 1996, pp. 1420-1420
Authors:
JOSHUA DE
Citation: De. Joshua, MYELOMA - NEW ASPECTS OF BIOLOGY, PROGNOSIS AND TREATMENT, Pathology, 28(1), 1996, pp. 2-7
Authors:
JOSHUA DE
BROWN RD
LUO XF
GIBSON J
Citation: De. Joshua et al., CIRCULATING CLONAL LYMPHOCYTES IN MYELOMA DETERMINED BY MESSENGER-RNAIN-SITU HYBRIDIZATION, Blood, 88(3), 1996, pp. 1125-1125
Authors:
BROWN RD
YUEN E
NELSON M
GIBSON J
JOSHUA DE
Citation: Rd. Brown et al., T-CELL CLONES IN MYELOMA - PROGNOSTIC-SIGNIFICANCE OF T-CELL RECEPTOR-BETA GENE REARRANGEMENTS AND CORRELATION WITH IDIOTYPE-REACTIVE T-CELLS, Blood, 88(10), 1996, pp. 2552-2552
Authors:
SEGALOV E
GIBSON J
JOSHUA DE
KRONENBERG H
Citation: E. Segalov et al., PRIMARY AMYLOIDOSIS CO-PRESENTING WITH CERVICAL AND MASSIVE INTRAABDOMINAL LYMPHADENOPATHY, Leukemia & lymphoma, 19(5-6), 1995, pp. 519-520
Authors:
JOSHUA DE
BROWN RD
GIBSON J
POPE B
PETERSEN A
FORSYTH C
Citation: De. Joshua et al., CHANGES IN THE PRIMITIVE PLASMA-CELL SUBPOPULATION DETERMINE THE CLINICAL STATE IN MYELOMA, Blood, 86(10), 1995, pp. 228-228
Authors:
JOSHUA DE
BROWN RD
GIBSON J
Citation: De. Joshua et al., PROGNOSTIC FACTORS IN MYELOMA - WHAT THEY TELL US ABOUT THE PATHOPHYSIOLOGY OF THE DISEASE, Leukemia & lymphoma, 15(5-6), 1994, pp. 375-381
Authors:
BISHOP JF
MATTHEWS JP
YOUNG G
SZER J
JOSHUA DE
DODDS A
LAIDLAW CR
COBCROFT R
HERRMAN R
MA D
PAGE FJ
Citation: Jf. Bishop et al., THE INFLUENCE OF INDUCTION CHEMOTHERAPY DOSE AND DOSE INTENSITY ON THE DURATION OF REMISSION IN ACUTE MYELOID-LEUKEMIA, Leukemia & lymphoma, 15(1-2), 1994, pp. 79-84
Authors:
PETERSEN AJ
BROWN RD
POPE BB
JAMIESON GP
PATERSON ARP
GIBSON J
WILEY JS
JOSHUA DE
Citation: Aj. Petersen et al., MULTIPLE-MYELOMA - EXPRESSION OF NUCLEOSIDE TRANSPORTERS ON MALIGNANTPLASMA-CELLS AND THEIR RELATIONSHIP TO CELLULAR PROLIFERATION, Leukemia & lymphoma, 13(5-6), 1994, pp. 491-499
Authors:
JOSHUA DE
GIBSON J
BROWN RD
Citation: De. Joshua et al., MECHANISMS OF THE ESCAPE PHASE OF MYELOMA, Blood reviews, 8(1), 1994, pp. 13-20
Authors:
SNOWDON L
GIBSON J
JOSHUA DE
Citation: L. Snowdon et al., FREQUENCY OF INFECTION IN PLATEAU-PHASE MULTIPLE-MYELOMA, Lancet, 344(8917), 1994, pp. 262-262
Authors:
JOSHUA DE
BROWN RD
GIBSON J
Citation: De. Joshua et al., MULTIPLE-MYELOMA - WHY DOES THE DISEASE ESCAPE FROM PLATEAU-PHASE, British Journal of Haematology, 88(4), 1994, pp. 667-671
Authors:
JOSHUA DE
PENNY R
BALDWIN R
LAIDLAW CR
MATTHEWS JP
Citation: De. Joshua et al., THE STUDY OF COMBINATION THERAPY PLUS OR MINUS ROFERON-A IN MULTIPLE-MYELOMA, Blood, 84(10), 1994, pp. 10000179-10000179
CARE - HIGH-DOSE CYTOSINE-ARABINOSIDE AND ETOPOSIDE IN RELAPSED AND REFRACTORY NON-HODGKINS-LYMPHOMA
Authors:
GIBSON J
MANSBERG R
JOSHUA DE
KRONENBERG H
Citation: J. Gibson et al., CARE - HIGH-DOSE CYTOSINE-ARABINOSIDE AND ETOPOSIDE IN RELAPSED AND REFRACTORY NON-HODGKINS-LYMPHOMA, Journal of cellular biochemistry, 1993, pp. 269-269
Authors:
BROWN RD
JOSHUA DE
NELSON M
GIBSON J
DUNN J
MACLENNAN ICM
Citation: Rd. Brown et al., SERUM THYMIDINE KINASE AS A PROGNOSTIC INDICATOR FOR PATIENTS WITH MULTIPLE-MYELOMA - RESULTS FROM THE MRC (UK) V-TRIAL, British Journal of Haematology, 84(2), 1993, pp. 238-241
Authors:
RALPH QM
BRISCO MJ
JOSHUA DE
BROWN R
GIBSON J
MORLEY AA
Citation: Qm. Ralph et al., ADVANCEMENT OF MULTIPLE-MYELOMA FROM DIAGNOSIS THROUGH PLATEAU-PHASE TO PROGRESSION DOES NOT INVOLVE A NEW B-CELL CLONE - EVIDENCE FROM THEIG HEAVY-CHAIN GENE, Blood, 82(1), 1993, pp. 202-206
Authors:
MANSBERG R
GIBSON J
JOSHUA DE
KRONENBERG H
Citation: R. Mansberg et al., CYTOSINE-ARABINOSIDE AND ETOPOSIDE (CARE) IN RELAPSED AND REFRACTORY NON-HODGKINS-LYMPHOMA, Medical oncology and tumor pharmacotherapy, 9(4), 1992, pp. 173-176
Risultati:
1-23
|